Today: 9 June 2026
Costco stock price dips as dividend lands; investors wait on sales and earnings
16 January 2026
1 min read

Costco stock price dips as dividend lands; investors wait on sales and earnings

New York, Jan 16, 2026, 12:15 EST — Regular session

Costco Wholesale shares edged lower on Friday as investors took in the company’s latest dividend declaration, with the broader market little changed.

The warehouse retailer’s stock was down about 0.1% at $955.35 in midday trade, lagging a flat S&P 500. Walmart and Target were also down, while BJ’s Wholesale slid more than 1%.

The timing matters because Costco’s next monthly sales snapshot is close. The company is scheduled to release January sales results on Feb. 4, an update traders use as an early read on store traffic and demand before the next earnings report.

The dividend itself is not a surprise for a steady cash generator, but it keeps the focus on what investors are paying for in retail right now: repeat business, predictable fees and less drama in the numbers.

Costco said its board declared a quarterly cash dividend of $1.30 per share, payable on Feb. 13 to shareholders of record as of Jan. 30. At Friday’s price, that’s an annualized $5.20 dividend, or roughly a 0.5% yield. The company said it operates 923 warehouses worldwide.

A separate regulatory filing showed some insider selling. Executive Vice President James C. Klauer sold 1,500 Costco shares at $939 on Jan. 14, a Form 4 filing showed — the document insiders file with the U.S. SEC to disclose stock trades.

Wall Street remains split on how much to pay for the name. Bernstein analyst Zhihan Ma argued this week that wide valuation gaps across retailers can be justified by growth and profitability, and described Costco as an “ultimate compounder,” according to a Barron’s report. Barron’s

Costco’s monthly sales updates have carried extra weight since the company reported December net sales rose 8.5% to $29.86 billion in the five weeks ended Jan. 4.

But the premium multiple cuts both ways. Any sign of softer comparable sales, higher wage and freight costs, or a hit from currency and gasoline price swings could sting a stock that investors often treat as a safe place to hide.

The next hard catalyst is the fiscal second-quarter earnings call on March 5, scheduled after the U.S. market close.

Stock Market Today

  • S&P 500 Rallies on Chipmaker Gains; Crude Oil Prices Retreat After Iran-Israel Ceasefire Signal
    June 9, 2026, 9:24 AM EDT. The S&P 500 gained +0.30% on Monday, driven by renewed investor interest in artificial intelligence boosting chipmakers. Nasdaq 100 rose +1.58%, while the Dow slipped -0.16%, dragged lower by Apple's -1% drop amid lukewarm AI platform feedback. Crude oil prices surged over +4% initially due to Iran-Israel tensions but retreated after Iran signaled an end to its current military operation. The market discounts a low 3% chance of a +25 basis point rate hike by the Federal Reserve on June 16-17. Treasury yields climbed, with 10-year notes reaching a two-week high of 4.58%, pressured by strong US jobs data and heavy upcoming Treasury auctions. Overseas markets closed mixed, with China's Shanghai Composite down -1.70% and Japan's Nikkei falling -3.85%.

Latest articles

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
AmpliTech’s 5G Radio Test Moves AMPG Shares

AmpliTech’s 5G Radio Test Moves AMPG Shares

9 June 2026
AMPG soared 26.7% to $6.57 after AmpliTech revealed its 64T64R Massive MIMO radio was the only one of its kind at O-RAN PlugFest, showing interoperability with major carriers’ equipment, but no new orders were announced, leaving sales conversion as the key investor focus.
Cartesian Growth Ticker Change Draws Trader Attention to Factorial Energy

Cartesian Growth Ticker Change Draws Trader Attention to Factorial Energy

9 June 2026
Factorial Energy surged 16% to $13.80 in its Nasdaq debut as FAC, with premarket trading near $20.70, after replacing CGCT via SPAC merger that raised over $100 million for battery commercialization and implied a $1.3 billion equity value; former CGCT shares now trade as FAC, with founders retaining majority voting power and staged lock-up releases ahead.
Pfizer Falls in Premarket; Fresh FDA Approval Not Lifting the Stock

Pfizer Falls in Premarket; Fresh FDA Approval Not Lifting the Stock

9 June 2026
Pfizer shares fell 1.7% premarket to $25.62 as investors weighed an FDA label expansion for hemophilia drug Hympavzi—now the first subcutaneous non-factor therapy for children 6-11 with hemophilia B—against slower progress in obesity drugs, with mid-stage data for weight-loss shot berobenatide showing a 23.3% vomiting rate and no immediate growth catalyst for the $147 billion company.
Denison Mines stock jumps with uranium names as Phoenix approvals come into focus
Previous Story

Denison Mines stock jumps with uranium names as Phoenix approvals come into focus

Western Digital (WDC) stock price: Analysts lift targets as SanDisk stake sale, earnings loom
Next Story

Western Digital (WDC) stock price: Analysts lift targets as SanDisk stake sale, earnings loom

Go toTop